Central nervous system shunt infection
Methodology & AI Transparency ⓘ
Central nervous system shunt infection Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Central nervous system shunt infection is an ICD-10-CM indexed diagnosis (T85.730A) within Bacterial, Viral & Fungal Infections.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM T85.730A for Central nervous system shunt infection clinical workups.
- 3 Typical cash cost range: Clinicians assessing Central nervous system shunt infection focus on cytokine pyrogen release [Central nervous system shunt infection T85.730A] and targeted history.
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for Central nervous system shunt infection (T85.730A): Targeted PCR / in Central nervous system shunt infection (T85.730A: Culture & Sensitivity) & Complete Blood Count in Central nervous system shunt infection (T85.730A: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (T85.730A)).
Ask our AI Specialists anything about Central nervous system shunt infection
What Is Central nervous system shunt infection?
Central nervous system shunt infection is an ICD-10-CM indexed diagnosis (T85.730A) within Bacterial, Viral & Fungal Infections. Clinical evaluation centers on bacterial/fungal culture with in Central nervous system shunt infection (T85.730A: antimicrobial susceptibility testing) alongside serial Targeted PCR / in Central nervous system shunt infection (T85.730A: Culture & Sensitivity) tracking (Pathogen clearance / negative test (T85.730A)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Central nervous system shunt infection (T85.730A) alters infections & antivirals homeostasis through cytokine pyrogen release [Central nervous system shunt infection T85.730A]; clinical remission targets Complete Blood Count in Central nervous system shunt infection (T85.730A: (WBC & Differential)) within WBC 4.0 – 10.0 x10^3/uL (T85.730A).
Common Symptoms & Clinical Signs
- • Presentation of Central nervous system shunt infection (T85.730A): painful vesicular rash in Central nervous system shunt infection (T85.730A: in a dermatomal)
- • Secondary Central nervous system shunt infection clinical sign: regional lymph node in Central nervous system shunt infection (T85.730A: tenderness or acute)
- • Symptom flares in Central nervous system shunt infection correlating with Targeted PCR / in Central nervous system shunt infection (T85.730A: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (T85.730A)
- • Functional infections & antivirals impact requiring bacterial/fungal culture with in Central nervous system shunt infection (T85.730A: antimicrobial susceptibility testing) evaluation (T85.730A)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Central nervous system shunt infection Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T85.730A | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in Central nervous system shunt infection (T85.730A: Culture & Sensitivity) | Pathogen clearance / negative test (T85.730A) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Central nervous system shunt infection (T85.730A: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (T85.730A) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Central nervous system shunt infection (T85.730A: Procalcitonin) | Resolution to baseline (T85.730A) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Central nervous system shunt infection
Treatment selection for Central nervous system shunt infection depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Central nervous system shunt infection)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Is adenotonsillectomy effective in improving central apnea events in patients: What a 1,287-Participant Study Found Adenotonsillectomy improves central apnea events in patients with OSA but not in those with comorbidities. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery • 2023-12-15 • Meta-Analysis | N = 1,287 | 94/100 | PMID 37642712 ↗ |
| New Insights on Participant, site personnel and sponsor perspectives on decentralized trial: What a 486-Participant Study Found RVs influenced the decision to pursue the trial in 13/31 participants. Amyotrophic lateral sclerosis & frontotemporal degeneration • 2025-11-15 • Phase III Randomized Trial | N = 486 | 93/100 | PMID 40576049 ↗ |
| New Insights on SGLT2 inhibitor or metformin as standard treatment in early-stage type 2: What a 2,072-Participant Study Found This decentralised RRCT in newly onset T2D demonstrates a highly feasible option for large-scale trials in the primary care setting, enabling representative participant recruitment. Diabetes, obesity & metabolism • 2026-02-15 • Randomized Controlled Trial | N = 2,072 | 90/100 | PMID 41311237 ↗ |
| Can This Approach Help? Inside the Latest Research on Central nervous system symptom burden and clinical implications for antiemetic CNS symptom burden was associated with suboptimal CINV control, while 5 mg of olanzapine maintained superior antiemetic efficacy across CNS symptom strata. The oncologist • 2026-09-09 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42714265 ↗ |
| Can This Approach Help? Inside the Latest Research on Randomised controlled decentralised feasibility trial of a fixed low-dose The feasibility of this decentralised trial on BP lowering in patients at high risk for dementia is low. BMJ open • 2024-08-24 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 39181551 ↗ |
Central nervous system shunt infection Patient Community & “People Like Me” Threads
Filter Central nervous system shunt infection community threads and patient logs by age, biological sex, dosage, and treatment duration.